Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | ITK | Q08881 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83376 | 0.80 | BRD4 (0.48) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL69073 | 0.78 | BRD4 (0.47) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| SCHEMBL13419405 | 0.77 | BRD4 (0.43) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| SCHEMBL82947 | 0.76 | BRD4 (0.48) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| Hydrochloric Acid SCHEMBL69124 | 0.75 | BRD4 (0.47) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| SCHEMBL6709573 | 0.74 | TSHR (0.41) | BRD4ATAD2MEN1KMT2AIRAK4 | |
| SCHEMBL22542015 | 0.74 | HTR2C (0.50) | MEN1CYP2D6KMT2AHTR2CSLC6A2 | |
| SCHEMBL427843 | 0.72 | BRD4 (0.41) | BRD4ATAD2MEN1CYP2D6KMT2A | |
| SCHEMBL13809337 | 0.72 | ALDH1A1 (0.57) | MEN1KMT2A | |
| Bromide SCHEMBL11023029 | 0.70 | HCAR3 (0.52) | MEN1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172270-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2011-07-14 | — | — | US | disclosed |
| US-20110172270-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2011-07-14 | — | — | US | disclosed |
| US-7888510-B2 | 1,4-disubstituted piperidine compounds like N-(9-Ethyl-9H-carbazol-3-yl)-2-[4-(2-hydroxymethyl-6-methyl-phenylamino)-piperidine-yl]acetamide; chloroacetyl chloride is reacted with respective compounds in the presence of dichloromethane and triethylamine or diisopropylethylamine | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-02-15 | — | — | US | disclosed |
| US-7888510-B2 | 1,4-disubstituted piperidine compounds like N-(9-Ethyl-9H-carbazol-3-yl)-2-[4-(2-hydroxymethyl-6-methyl-phenylamino)-piperidine-yl]acetamide; chloroacetyl chloride is reacted with respective compounds in the presence of dichloromethane and triethylamine or diisopropylethylamine | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2011-02-15 | — | — | US | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| US-20080119516-A1 | 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| US-20080119516-A1 | 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-05-22 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119516-A1 | 2-'4(Phenylamino)-Piperidin-1-Yl!-N-Phenyl-Acetamine Derivatives and Related Compounds as Neuropeptide Y5 (NPY5) Ligands for the Treatment of Obesity | NPY5R, NPY1R, NPY4R | BRD4 1090/4885ATAD2 1272/4885MEN1 1541/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | BRD4 1757/4885ATAD2 4385/4885MEN1 1861/4885 |
| US-20110172270-A1 | 2-'4(PHENYLAMINO)-PIPERIDIN-1-YL!-N-PHENYL-ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE TREATMENT OF OBESITY | NPY5R, NPY1R, NPY4R | BRD4 1279/4885ATAD2 1582/4885MEN1 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.